ImmunityBio (IBRX) Accumulated Depreciation & Amortization (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Accumulated Depreciation & Amortization data on file, last reported at $4.4 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization rose 14.39% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 14.39% YoY) and the FY2025 annual result came in at $15.5 million, down 11.56% from the prior year.
• Accumulated Depreciation & Amortization fell to $4.4 million in Q1 2026 per IBRX's latest filing, from $15.5 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $18.5 million in Q4 2023 and bottomed at $3.8 million in Q1 2025.
• The 5-year median for Accumulated Depreciation & Amortization is $9.4 million (2023), against an average of $10.5 million.
• The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization surged 37.62%; it then declined 15.94% in 2025.
• Tracing IBRX's Accumulated Depreciation & Amortization over 5 years: stood at $18.3 million in 2022, then advanced by 1.38% to $18.5 million in 2023, then decreased by 5.18% to $17.6 million in 2024, then slipped by 11.56% to $15.5 million in 2025, then slumped by 71.79% to $4.4 million in 2026.
• Per Business Quant, the three latest IBRX Accumulated Depreciation & Amortization figures stand at $4.4 million (Q1 2026), $15.5 million (Q4 2025), and $11.7 million (Q3 2025).

Peer Comparison